Calando Pharmaceuticals Will Jointly Develop RNAi Therapeutics to Battle Childhood Cancer with National Cancer Institute
NCI To Co-Sponsor â€˜Nanotechnology for Cancer Prevention, Diagnosis and Treatmentâ€™ Symposium at Nanotech 2006 Conference in Boston.
Arrowhead Research Corporationâ€™s majority-owned subsidiary Calando Pharmaceuticals, Inc. and the National Cancer Institute (NCI) have jointly established a development program to develop RNA interference (RNAi) therapeutics to fight one form of childhood cancer. RNAi is a technique that has been found to "silence" the expression of genes that cause diseases. _ The partnership with the NCI's Pediatric Oncology Branch will focus on developing RNAi therapeutics to attack neuroblastoma, the most common solid tumor found outside of the brain cavity in children younger than five. The program between Calando and the NCI is expected to last a minimum of three years, from preclinical research through to human clinical trials. Calando and the NCI will also share in developing the therapeutics.
To learn more about the NCI and the latest cancer research using nanoscale technologies being conducted around the country, the NCI is co-sponsoring a Special Symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment at the NSTI Nanotech 2006 Conference in Boston in May. The full program for NSTI Nanotech 2006 can be found at http://www.nsti.org/Nanotech2006/.